SARS-CoV-2 infection
Conditions
Interventions
no-treatment control group:Shufeng Jiedu Capsules (COVID-19 recommended general treatment plan for the ninth version)
Treatment group 1:Lentinan 25ug/d×5 days+Shufeng Jiedu Capsules (COVID-19 recommended general treatment plan for the ninth version)
Treatment group 2:Lentinan 50ug/d×5 days+Shufeng Jiedu Capsules (COVID-19 recommended general treatment plan for the ninth version)
Treatment group 3:Lentinan 100ug/d×5 days+Shufeng Jiedu Capsules (COVID-19 recommended general treatment plan for the ninth version)
Sponsors
The First Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary signing of informed consent form 2. At least 18 years old but less than 60 years old; Gender unlimited 3. Within 5 days prior to screening, with or without COVID-19 related symptoms, SARS-CoV-2 infection was confirmed through PCR detection within 24 hours; 4. Agree not to participate in other interventional clinical trials for the treatment of SARS-CoV-2 during the study period 5. Agree to the detailed sampling requirements in the evaluation schedule and comply with the research requirements
Exclusion criteria
Exclusion criteria: 1. COVID-19 positive patients; 2. Patients with bleeding tendencies 3. Allergy to shiitake mushroom polysaccharides or their pharmaceutical components; 4. Have experienced severe allergic reactions, including systemic urticaria, vascular edema, and hypersensitivity reactions 5. Received COVID-19 rehabilitation plasma and SARS-CoV-2 antibody treatment; 6. Have received other investigational drugs for the treatment of COVID-19; 7. Pregnant or lactating women; 8. Those who merge with other serious systemic diseases; 9. According to the judgment of the researcher, it is deemed unsuitable to participate in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virus negative rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in viral load in nasopharyngeal swabs/respiratory secretions after medication;Hospital discharge rate;Clinical outcome; | — |
Countries
China
Contacts
Public ContactXuesong Liang
Department of Infectious Diseases, Changhai Hospital Affiliated to Naval Military Medical
Outcome results
None listed